Prothena Corporation plc (PRTA) - Total Assets
Based on the latest financial reports, Prothena Corporation plc (PRTA) holds total assets worth $352.63 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Prothena Corporation plc - Total Assets Trend (2010–2024)
This chart illustrates how Prothena Corporation plc's total assets have evolved over time, based on quarterly financial data. Also see market value of Prothena Corporation plc for the company's overall valuation and market capitalisation.
Prothena Corporation plc - Asset Composition Analysis
Current Asset Composition (December 2024)
Prothena Corporation plc's total assets of $352.63 Million consist of 88.7% current assets and 11.3% non-current assets. Review debt load of Prothena Corporation plc to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 86.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2010–2024)
This chart illustrates how Prothena Corporation plc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Prothena Corporation plc share price for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Prothena Corporation plc's current assets represent 88.7% of total assets in 2024, an increase from 0.0% in 2010.
- Cash Position: Cash and equivalents constituted 86.2% of total assets in 2024, up from 0.0% in 2010.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2010.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Prothena Corporation plc Competitors by Total Assets
Key competitors of Prothena Corporation plc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Prothena Corporation plc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.61 | 11.52 | 11.58 |
| Quick Ratio | 6.61 | 11.52 | 11.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $288.54 Million | $488.56 Million | $273.44 Million |
Prothena Corporation plc - Advanced Valuation Insights
This section examines the relationship between Prothena Corporation plc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.62 |
| Latest Market Cap to Assets Ratio | 0.82 |
| Asset Growth Rate (YoY) | -21.4% |
| Total Assets | $547.11 Million |
| Market Capitalization | $448.40 Million USD |
Valuation Analysis
Near Book Valuation: The market values Prothena Corporation plc's assets close to their book value (0.82x), suggesting investors view the company's assets at approximately fair value.
Significant Asset Reduction: Prothena Corporation plc's assets decreased by 21.4% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Prothena Corporation plc (2010–2024)
The table below shows the annual total assets of Prothena Corporation plc from 2010 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $547.11 Million | -21.44% |
| 2023-12-31 | $696.38 Million | -8.13% |
| 2022-12-31 | $758.03 Million | +24.40% |
| 2021-12-31 | $609.37 Million | +83.01% |
| 2020-12-31 | $332.98 Million | -20.58% |
| 2019-12-31 | $419.27 Million | -15.94% |
| 2018-12-31 | $498.80 Million | +0.50% |
| 2017-12-31 | $496.33 Million | +7.90% |
| 2016-12-31 | $459.98 Million | +19.40% |
| 2015-12-31 | $385.24 Million | +26.67% |
| 2014-12-31 | $304.12 Million | +66.72% |
| 2013-12-31 | $182.41 Million | +41.09% |
| 2012-12-31 | $129.28 Million | +3473.33% |
| 2011-12-31 | $3.62 Million | +9.64% |
| 2010-12-31 | $3.30 Million | -- |
About Prothena Corporation plc
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson… Read more